Did the adverse event appear after the suspect drug was administered?
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Did the AR improve when the drug was discontinued or a specifi c antagonist was administered?
Did the AR reappear when drug was re-administered?
Are there alternate causes (other than the drug) that could solely have caused the reaction?
Did the reaction reappear when a placebo was given?
Was the drug detected in the blood (or other fl uids) in a concentration known to be toxic?
Was the reaction more severe when the dose was increased or less severe when the dose was decreased?
Did the patient have a similar reaction to the same or similar drugs in any previous exposure?
Was the adverse event confi rmed by objective evidence?
Scoring for Naranjo's algorithm; >9 = defi nite ADR; 5-8 = probable ADR; 1-4 = possible ADR; 0 = doubtful ADR the literature." [1] We would like to make the following comments:
Recognition of adverse drug effects (ADRs) and establishing a causal relationship between the drug and the adverse event is essential. The authors should have objectively assessed and presented "Cilazapril-induced pleural effusion" based on an acceptable "Probability Scale." The causality assessment system proposed by the World Health Organization Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre (WHO-UMC) and the Naranjo probability scale are the generally accepted and most widely used methods for causality assessment in clinical practice as they offer a simple methodology. [2, 3] They are well-structured, consistent and easy to apply assessment methods. Tables 1 and 2 summarise the "Naranjo ADR Probability Scale" and the WHO-UMC causality system, respectively. [2, 3] We request the Editors that Annals of Thoracic Medicine should use either of the above two scales while reviewing articles related to ADRs.
